MB
INBX

MPM BioImpact’s Inhibrx, Inc. Common Stock INBX Stock Holding History

MPM BioImpact’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,192,281
Closed -$22.5M – 41
2023
Q1 		$22.5M Sell
1,192,281
-94,154
-7% -$2.19M 5.85% 5
2022
Q4 		$31.7M Buy
1,286,435
+6,440
+0.5% +$189K 8.22% 3
2022
Q3 		$23M Buy
1,279,995
+256,670
+25% +$4.63M 5.44% 3
2022
Q2 		$11.6M Buy
+1,023,325
New +$15.1M 3.23% 8

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

MPM BioImpact's INBX Position: Q2 2023 in Review

MPM BioImpact sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2023, closing a stake of 1,192,281 shares — an estimated $22.5M sold.

MPM BioImpact first reported a position in INBX in Q2 2022 and held it in 4 quarters. The position peaked at $31.7M in Q4 2022. 107 funds tracked by Wall St. Rank hold INBX as of Q2 2023.

  • MPM BioImpact reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • MPM BioImpact sold 1,192,281 Inhibrx, Inc. Common Stock shares in Q2 2023, an estimated $22.5M.
  • MPM BioImpact first reported a position in Inhibrx, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • MPM BioImpact's Inhibrx, Inc. Common Stock position peaked at $31.7M in Q4 2022.
  • 107 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2023.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.